image

Posters & Presentations

Our Process of Scientific Discovery

Nurix’s dedicated scientists are changing the landscape of cancer treatment. Learn more about our leading-edge research and drug development technology by exploring our presentations, videos, and mechanisms of action.

Filter by
  • Year
    • 2022
    • 2021
    • 2020
  • Program
    • NX-2127
    • NX-5948
    • NX-1607
    • DeTIL-0255
  • Platform
    • Targeted Protein Degradation
    • Targeted Protein Elevation
    • Drug-enhanced cell therapy
    • DELigase
    • Other
Chemistry @Nurix: Protein Modulation for Drug Discovery

Chemistry @Nurix: Protein Modulation for Drug Discovery

Bay Area Chemistry Symposium
Thursday, November 10, 2022
The-CBL-B-Inhibitor,-NX-0255,-Improves-Human-Drug-Enhanced-Tumor-Infiltrating-Lymphocyte-(DeTIL-0255)-Expansion-and-T-cell-Function-in-Full-scale-Runs-thumb

The CBL-B Inhibitor, NX-0255, Improves Human Drug Enhanced Tumor Infiltrating Lymphocyte (DeTIL-0255) Expansion and T-cell Function in Full-scale Runs 

SITC 37th Annual Meeting
Thursday, November 10, 2022
DeTIL 0255 Ovarian SITC 2022 poster 22 Oct 2022

Universal Expansion of CBL-B–inhibited Tumor-Infiltrating Lymphocytes, DeTIL-0255, from Women with Ovarian Cancer: Process Validation 

SITC 37th Annual Meeting
Thursday, November 10, 2022
A-Phase-1-Adoptive-Cell-Therapy-Using-Drug-Enhanced,-Tumor-Infiltrating-Lymphocytes,-DeTIL-0255,-in-Adults-With-Advanced-Malignancies-thumb

A Phase 1 Adoptive Cell Therapy Using Drug-Enhanced, Tumor-Infiltrating Lymphocytes, DeTIL-0255, in Adults With Advanced Malignancies 

SITC 37th Annual Meeting
Thursday, November 10, 2022
Initial-Clinical-Characterization-of-Novel-Proximal-Biomarkers-for-NX-1607,-a-First-in-Class-Oral-CBL-B-Inhibitor,-in-Patients-with-Advanced-Malignancies-thumb

Initial Clinical Characterization of Novel Proximal Biomarkers for NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Malignancies 

SITC 37th Annual Meeting
Thursday, November 10, 2022
A-Novel-Small-Molecule-Inhibitor-of-CBL-B-Shows-Potent-Antitumor-Activity-in-Combination-with-Pmel-1-Adoptive-Cell-Transfer-in-an-Aggressive-Mouse-Melanoma-Model-thumb

A Novel Small Molecule Inhibitor of CBL-B Shows Potent Antitumor Activity in Combination with Pmel-1 Adoptive Cell Transfer in an Aggressive Mouse Melanoma Model 

SITC 37th Annual Meeting
Thursday, November 10, 2022
NX-1607,-a-Small-Molecule-Inhibitor-of-the-CBL-B-E3-Ubiquitin-Ligase,-Promotes-T-and-NK-Cell-Activation-and-Enhances-NK-mediated-ADCC-in-a-Mouse-Lymphoma-Tumor-Model-thumb

NX-1607, a Small Molecule Inhibitor of the CBL-B E3 Ubiquitin Ligase, Promotes T and NK Cell Activation and Enhances NK-mediated ADCC in a Mouse Lymphoma Tumor Model 

SITC 37th Annual Meeting
Thursday, November 10, 2022
The First BTK Degraders in Hematologic Malignancies: The Latest from the Clinic

The First BTK Degraders in Hematologic Malignancies: The Latest from the Clinic

5th Annual TPD Summit
Wednesday, October 26, 2022
Utilizing DEL as a Primary Discovery Engine for Targeted Protein Degradation

Utilizing DEL as a Primary Discovery Engine for Targeted Protein Degradation

5th Annual TPD Summit
Wednesday, October 26, 2022
5th Annual TPD Summit

Discovery of Orally Active, Brain-Penetrant, Targeted Protein Degraders

5th Annual TPD Summit
Wednesday, October 26, 2022
Combining-TIL-with-Small-Molecule-Inhibitors-to-Enhance-T-Cell-Expansion-&-Phenotypes-thumb

Combining TIL with Small Molecule Inhibitors to Enhance T-Cell Expansion & Phenotypes

4th TIL Therapies Summit
Tuesday, October 25, 2022
Discovery-and-Optimization-of-CBL-B-Inhibitors-thumb

Discovery and Optimization of CBL-B Inhibitors 

Discovery On Target
Tuesday, October 18, 2022
NX-1607,-an-inhibitor-of-the-CBL-B-E3-ubiquitin-ligase,-promotes-favorable-local-and-systemic-changes-in-infiltrating-immune-cells-in-multiple-mouse-tumor-models-thumb

NX-1607, an inhibitor of the CBL-B E3 ubiquitin ligase, promotes favorable local and systemic changes in infiltrating immune cells in multiple mouse tumor models 

CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference
Friday, September 30, 2022
Inhibitors-of-the-E3-Ubiquitin-Ligase-CBL-B-Promote-Potent-T-and-NK-Cell-Mediated-Anti-Tumor-Response-thumb

Inhibitors of the E3 Ubiquitin Ligase CBL-B Promote Potent T and NK Cell Mediated Anti-Tumor Response

Non-Small Cell Lung Cancer Drug Development Summit
Wednesday, September 21, 2022
First-Targeted-Protein-Degrader-for-Hematologic-Malignancies-thumb

First Targeted Protein Degrader for Hematologic Malignancies

Promega TPD Symposium
Tuesday, September 20, 2022
Discovery-and-Optimization-of-CBL-B-Inhibitors-Thumb

Discovery and Optimization of CBL-B Inhibitors

ACS Fall Meeting
Tuesday, August 23, 2022
Exploring-NX-5948--A-CNS-Penetrant-Selective-Degrader-of-BTK-that-Significantly-Reduces-Inflammation-in-Mouse-Models-of-Autoimmune-Disease-thumb

Exploring NX-5948: A CNS Penetrant Selective Degrader of BTK that Significantly Reduces Inflammation in Mouse Models of Autoimmune Disease 

3rd Annual B & T Cell-Mediated Autoimmune Disease Drug Development Summit
Wednesday, July 27, 2022
A-First-in-Human-Phase-1-Trial-of-NX-2127,-a-First-in-Class-Oral-BTK-Degrader-With-Immunomodulatory-Activity,-in-Patients-With-Relapsed-and-Refractory-B-Cell-Malignancies-thumb

A First-in-Human Phase 1 Trial of NX-5948, an Oral BTK Degrader, in Patients with Relapsed and Refractory B-cell Malignancies

European Hermatology Association (EHA) 2022 Hybrid Congress
Thursday, June 9, 2022
European-Hermatology-Association-EHA-2022-Hybrid-Congress-thumb

A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Oral BTK Degrader With Immunomodulatory Activity, in Patients With Relapsed and Refractory B-Cell Malignancies

European Hermatology Association (EHA) 2022 Hybrid Congress
Thursday, June 9, 2022
The-CBL-B-Inhibitor,-NX-0255,-Enhances-Human-Drug-Enhanced-Tumor-Infiltrating-Lymphocyte-(DeTIL)-Expansion-and-T-Cell-Function-in-Full-Scale-Runs-thumb

The CBL-B Inhibitor, NX-0255, Enhances Human Drug-Enhanced Tumor-Infiltrating Lymphocyte (DeTIL) Expansion and T Cell Function in Full-Scale Runs

24th Annual Translational Research Cancer Centers Consortium (TRCCC) Meeting
Monday, June 6, 2022
A-Phase-1-Adoptive-Cell-Therapy-Using-Drug-Enhanced,-Tumor-Infiltrating-Lymphocytes,-DeTIL-0255,-in-Adults-With-Advanced-Malignancies-thumb

A Phase 1 Adoptive Cell Therapy Using Drug-Enhanced, Tumor-Infiltrating Lymphocytes, DeTIL-0255, in Adults With Advanced Malignancies

24th Annual Translational Research Cancer Centers Consortium (TRCCC) Meeting
Monday, June 6, 2022
Modeling-Limit-of-Detection-for-Dominant-T-Cell-Receptor-Clones-Reveals-Comparable-Measures-Across-RNA-and-DNA-Based-Sequencing-thumb

Modeling Limit of Detection for Dominant T Cell Receptor Clones Reveals Comparable Measures Across RNA and DNA Based Sequencing

24th Annual Translational Research Cancer Centers Consortium (TRCCC) Meeting
Monday, June 6, 2022
A-Phase-1-Adoptive-Cell-Therapy-Using-Drug-Enhanced,-Tumor-Infiltrating-Lymphocytes,-DeTIL-0255,-in-Adults-With-Advanced-Malignancies-thumb

A Phase 1 Adoptive Cell Therapy Using Drug-Enhanced, Tumor-Infiltrating Lymphocytes, DeTIL-0255, in Adults With Advanced Malignancies

American Society of Clinical Oncology (ASCO) Annual Meeting
Friday, June 3, 2022
A-First-in-Human-Phase-1-Trial-of-NX-2127,-a-First-in-Class-Oral-BTK-Degrader-With-Immunomodulatory-Activity,-in-Patients-With-Relapsed-and-Refractory-B-Cell-Malignancies-thumb

A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Oral BTK Degrader With Immunomodulatory Activity, in Patients With Relapsed and Refractory B-Cell Malignancies

American Society of Clinical Oncology (ASCO) Annual Meeting
Friday, June 3, 2022
A-First-in-Human-Phase-1-Trial-of-NX-1607,-a-First-in-Class-Oral-CBL-B-Inhibitor,-in-Patients-with-Advanced-Solid-Tumors-thumb

A First-in-Human Phase 1 Trial of NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Solid Tumors

American Society of Clinical Oncology (ASCO) Annual Meeting
Friday, June 3, 2022

R&D Day

New York, NY
Thursday, May 26, 2022
Application-of-DNA-Encoded-Libraries-to-Discover-Small-Molecules-for-E3-Ligase-Modulation-Thumb

Application of DNA-Encoded Libraries to Discover Small Molecules for E3 Ligase Modulation

2nd Annual Ligase Targeting Drug Development
Thursday, April 28, 2022
Applying-DEL-Discovery-to-Protein-Modulation-Thumb

Applying DEL Discovery to Protein Modulation

17th Annual Drug Discovery Chemistry
Tuesday, April 19, 2022
Inhibitors-of-the-E3-Ubiquitin-Ligase-CBL-B-Promote-Potent-T-and-NK-Cell-Mediated-Anti-Tumor-Response-Thumb

Inhibitors of the E3 Ubiquitin Ligase CBL-B Promote Potent T and NK Cell Mediated Anti-Tumor Response

17th Annual Drug Discovery Chemistry
Tuesday, April 19, 2022
Concurrent-degradation-of-BTK-and-IMiD-neosubstrates-by-NX-2127-enhances-multiple-mechanisms-of-tumor-killing-Thumb

Concurrent degradation of BTK and IMiD neosubstrates by NX-2127 enhances multiple mechanisms of tumor killing

American Association for Cancer Research (AACR) 2022 Annual Meeting
Tuesday, April 12, 2022
Ex-vivo-inhibition-of-CBL-B-with-a-novel-small-molecule-inhibitor-NX-0255-enhances-persistence-and-anti-tumor-activity-of-adoptively-transferred-CD8-T-cells-in-mouse-tumor-models-Thumb

Ex-vivo inhibition of CBL-B with a novel small molecule inhibitor, NX-0255, enhances persistence and anti-tumor activity of adoptively transferred CD8+ T cells in mouse tumor models

American Association for Cancer Research (AACR) 2022 Annual Meeting
Friday, April 8, 2022
NX‑5948-a-Selective-Degrader-of-BTK-With-Activity-in-Preclinical-Models-of-Hematologic-and-Brain-Malignancies-Thumb

NX‑5948, a Selective Degrader of BTK With Activity in Preclinical Models of Hematologic and Brain Malignancies

63rd American Society of Hematology (ASH) Annual Meeting
Sunday, December 12, 2021
NX‑0255-a-Small‑Molecule-CBL‑B-Inhibitor-Expands-and-Enhances-Tumor‑Infiltrating-Thumb

NX‑0255, a Small‑Molecule CBL‑B Inhibitor, Expands and Enhances Tumor‑Infiltrating
Lymphocytes for Use in Adoptive Cancer Immunotherapy

Society for Immunotherapy of Cancer 36th Annual Meeting
Friday, November 12, 2021
First-Demonstration-of-Targeted-Protein-Degradation-of-BTK-in-Hematologic-MalignanciesInitial-NX-2127-Phase-1a-PK-PD-Data-Thumb

First Demonstration of Targeted Protein Degradation of BTK in Hematologic Malignancies: Initial NX-2127 Phase 1a PK/PD Data

4th Annual Targeted Protein Degradation Summit
Wednesday, October 27, 2021
Nurix-Therapeutics-Presentation-Thumb

Nurix Therapeutics Presentation

European Protein Degradation Congress Presentation
Wednesday, September 22, 2021
NX-5948-a-Selective-Degrader-of-BTK-Significantly-Reduces-Inflammation-in-a-Model-of-Autoimmune-Disease-Thumb

NX-5948, a Selective Degrader of BTK, Significantly Reduces Inflammation in a Model of Autoimmune Disease

European Alliance of Associations for Rheumatology (EULAR) 2021 Virtual Congress
Wednesday, June 2, 2021
Small-molecule-inhibition-of-the-ubiquitin-ligase-CBL-B-with-NX-1607-results-in-potent-T-and-NK-cell-mediated-anti-tumor-response-Thumb

Small molecule inhibition of the ubiquitin ligase CBL-B with NX-1607 results in potent T and NK cell mediated anti-tumor response

American Association for Cancer Research (AACR) 2021 Annual Meeting
Saturday, April 10, 2021
NX-2127-a-Degrader-of-BTK-and-IMiD-Neosubstrates-for-the-Treatment-of-B-Cell-Malignancies-Thumb

NX-2127, a Degrader of BTK and IMiD Neosubstrates, for the Treatment of B-Cell Malignancies

62nd American Society of Hematology (ASH) Annual Meeting
Monday, December 7, 2020
Targeted-Protein-ModulationHarnessing-or-Inhibiting-E3-Ligases-to-Decrease-or-Increase-Protein-Levels-Thumb

Targeted Protein Modulation: Harnessing or Inhibiting E3 Ligases to Decrease or Increase Protein Levels

3rd Targeted Protein Degradation Summit 2020
Wednesday, October 14, 2020
MENU '